Correspondence 1397 ease and possibly of ALL. Since we did not detect any mutations on RARRES3 in cases with 11q deletions, we discussed in our paper that other alterations or mutations not involving the RARRES3 coding region itself but modifying regulatory sequences may be responsible for the observed down-regulation of this gene. Thus, we have contemplated the possibility of other alterations including the existence of novel tumor suppressor genes. As we discuss in our paper, further functional studies will be necessary to determine the exact role of RARRES3 in the development and progression of hematopoietic neoplasms.
Response to Garcia-Pardo
Leukemia (2002) 16, 1397. doi:10.1038/sj.leu.2402507
TO THE EDITOR
We are aware that Casanova et al 1 were not responsible for the original mapping of RARRES3, however, inconsistencies in gene positions need to be highlighted following publication of the human genome sequence. The GenBank accession NM-004585 references the DiSepio paper and localises RARRES3 to within cosmid 187d6. The NCBI Map Viewer, which provides a graphical display of the human genomic sequence data, place RARRES3 within the NT-009296.5. contig at 11q12. BLAST analysis produces significant alignment with four different overlapping 11q12 BAC clones, RP-11 838I13 (AC090088), CMB9-14B22 (AP000484), CTC-343D6 (AC090271) RP-11 660B16 (AC073228), including ones mapped by FISH to 11q12. This confirms the localisation of RARRES3 to 11q12 by at least two methodologies. In addition, it is worth consideration that the original mapping data for cosmid 187D6 was based only on a short sequence of homology and is at best weak. It is of importance that the mistaken placing of RARRES3 to 11q23 is not perpetuated. In our opinion it would be
Reply to Auer
Leukemia (2002) 16, 1397. doi:10.1038/sj.leu.2402508 TO THE EDITOR The RARRES3 gene described in our study 1 was originally assigned to the 11q23 region. 2 Although some databases still place this gene at that location, further examination and analyses after completion of the human genome sequence reveal that the correct position of RARRES3 is at 11q12, as pointed out and documented by Dr Auer et al, in their letters to Leukemia.
In spite of the new mapping of RARRES3 to 11q12, we observed a significant down-regulation of this gene in B-CLL patients including those with 11q23 deletions. As we discussed, RARRES3 may not be the targeted gene in these cases and other alterations including the existence of novel tumor suppressor genes have to be considered at this time. appropriate that the authors acknowledge this for the benefit of future research in CLL. Whilst we appreciate that the authors have shown down-regulation of RARRES3, which correlates with progression of CLL, this gene cannot be considered responsible for the 11q22-3 deletions associated with aggressive CLL. We do not dispute their findings for the RARRES3 gene and consider this of interest.
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